Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Nuvalent, Inc.

Get SEC filing alerts via email and in your feed for Nuvalent, Inc.

NUVL

Nuvalent, Inc.

About Nuvalent, Inc.

Nuvalent, Inc. is a biopharmaceutical company developing targeted small molecule therapies for cancer, focusing on kinase inhibitors like ROS1, ALK, and HER2. Its pipeline includes innovative, selective, brain-penetrant drugs aimed at overcoming resistance and off-target effects. The company emphasizes structure-based drug design, efficient discovery, and potential rapid regulatory pathways to deliver novel treatments for patients with solid tumors.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Nuvalent, Inc.

1
1
Nuvalent, Inc. Nuvalent Reports $109.3 Million Net Loss in Q1 2026, Increases R&D Spending

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Nuvalent, Inc. Nuvalent Reports $425.4 Million Net Loss for 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Nuvalent, Inc. Nuvalent Reports $122.4 Million Net Loss in Q3 2025, Driven by Increased R&D Expenses

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Nuvalent, Inc. Nuvalent Reports $99.7 Million Net Loss in Q2 2025 Amid Increased R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Nuvalent, Inc. Nuvalent Reports Increased Net Losses of $84.6 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Nuvalent, Inc. Nuvalent Reports Significant Asset Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments